 Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader SERD rintodestrant for ER, HER2- breast cancer Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader SERD rintodestrant for ER, HER2- breast cancer 